null Option on INmune Bio

INMB Stock  USD 7.95  0.07  0.87%   
INmune Bio's latest option contracts expiring on April 17th 2025 are carrying combined implied volatility of 1.99 with a put-to-call open interest ratio of 0.84 over 14 outstanding agreements suggesting investors are buying slightly more calls than puts on contracts expiring on April 17th 2025.

Open Interest Against April 17th 2025 Option Contracts

107.5Calls Open InterestPuts Open Interest100%
The chart above shows INmune Bio's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. INmune Bio's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for INmune Bio's option, there is no secondary market available for investors to trade.

In The Money vs. Out of Money Option Contracts on INmune Bio

Analyzing INmune Bio's in-the-money options over time can help investors to take a profitable long position in INmune Bio regardless of its overall volatility. This is especially true when INmune Bio's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money INmune Bio's options could be used as guardians of the underlying stock as they move almost dollar for dollar with INmune Bio's stock while costing only a fraction of its price.
In The Money Calls:Out Of Money Calls:In The Money Puts:Out Of Money Puts:100%
INmune Bio's stock options are financial instruments that give investors the right to buy or sell shares of INmune Bio common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell INmune stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If INmune Bio's stock price goes up or down, the stock options follow.
At present, INmune Bio's Common Stock is projected to increase significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 192.2 M, whereas Total Stockholder Equity is forecasted to decline to about 33.6 M.

INmune Bio In The Money Call Balance

When INmune Bio's strike price is surpassing the current stock price, the option contract against INmune Bio stock is said to be in the money. When it comes to buying INmune Bio's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Out Of The Money57.14%In The Money42.86%100%
While 'out-of-the-money' option contracts written on INmune Bio are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

INmune Current Options Market Mood

INmune Bio's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps INmune Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
45.5%

Put-to-Call Open Interest

100.0%

Put-to-Call Volume

Unfortunately, most INmune Bio's options investors are not very successful. INmune Bio's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current INmune contract

Base on the Rule 16, the options market is currently suggesting that INmune Bio will have an average daily up or down price movement of about 0.12% per day over the life of the 2025-04-17 option contract. With INmune Bio trading at USD 7.95, that is roughly USD 0.009888. If you think that the market is fully incorporating INmune Bio's daily price movement you should consider buying INmune Bio options at the current volatility level of 1.99%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Purchasing INmune Bio options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" INmune calls. Remember, the seller must deliver INmune Bio stock to the call owner when a call is exercised.

INmune Bio Option Chain

When INmune Bio's strike price is surpassing the current stock price, the option contract against INmune Bio stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
INmune Bio's option chain is a display of a range of information that helps investors for ways to trade options on INmune. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for INmune. It also shows strike prices and maturity days for a INmune Bio against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
INMB250417C00017500017.50.0 - 0.750.75Out
Call
INMB250417C000150001515.00.0 - 0.750.5Out
Call
INMB250417C00012500012.50.0 - 4.84.8Out
Call
INMB250417C000100003310.00.15 - 2.80.3Out
Call
INMB250417C00007500167.50.5 - 3.11.19In
Call
INMB250417C00005000275.02.6 - 3.93.29In
Call
INMB250417C0000250002.54.8 - 6.14.8In
 Put
INMB250417P00017500017.58.9 - 11.08.9In
 Put
INMB250417P00015000015.06.4 - 8.66.4In
 Put
INMB250417P00012500112.53.5 - 5.94.3In
 Put
INMB250417P00010000010.00.0 - 4.34.3In
 Put
INMB250417P00007500757.50.5 - 1.00.8Out
 Put
INMB250417P0000500005.00.0 - 0.750.75Out
 Put
INMB250417P0000250002.50.0 - 0.750.75Out

INmune Bio Market Cap Over Time

   Market Cap   
       Timeline  

INmune Total Stockholder Equity

Total Stockholder Equity

33.65 Million

At present, INmune Bio's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting.

INmune Bio Corporate Management

Christopher BarnumHead NeuroscienceProfile
BSc FRCPathChief OfficerProfile
Raymond MDPresident, CoFounderProfile
Joshua EsqGeneral CounselProfile
David MBATreasurer CFOProfile
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.18)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.63)
Return On Assets
(0.45)
Return On Equity
(0.99)
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

TCRX
Tscan Therapeutics
1.86  -0.12  -6.06 
DBTX
Decibel Therapeutics
0.00  0.00  0.00 
TFFP
Tff Pharmaceuticals
0.00  0.00  0.00 
DRMA
Dermata Therapeutics
1.26  0.05  4.13 
INAB
In8bio Inc
0.25  -0.01  -3.85 
AVTE
Aerovate Therapeutics
2.48  -0.05  -1.98 
ABCM
Abcam PLC
0.00  0.00  0.00 
BIVI
Biovie Inc
1.09  -0.1  -8.4 
SAVA
Cassava Sciences
2.67  -0.14  -4.98 
ANIX
Anixa Biosciences
2.63  -0.21  -7.39 
CUE
Cue Biopharma
1.03  -0.07  -6.36 
ANEB
Anebulo Pharmaceuticals
1.12  0.05  4.67 
ELYM
ELYM Old
0.00  0.00  0.00 
AVXL
Anavex Life Sciences
8.99  0.32  3.69 
PYPD
PolyPid
2.74  -0.13  -4.53 
CGTX
Cognition Therapeutics
0.41  -0.02  -4.65 
ANTX
AN2 Therapeutics
1.35  0.04  3.05 
News Freq…Investor S…